Drug intelligence / Profile preview

metformin + simvastatin

Development stage: Unknown
Lead developer: Merck KGaA
Modality: Small Molecules
Administration: Oral

Overview

A combination of two medications used to treat metabolic disorders. Metformin is an oral antidiabetic medication that enhances insulin sensitivity and regulates lipid metabolism, while simvastatin is a statin that lowers cholesterol levels. The combination has shown superior efficacy compared to metformin alone in treating polycystic ovary syndrome (PCOS), with advantages in improving sex hormones, blood lipids, and blood sugar levels.

Other names: metformin and simvastatin combinationneoadjuvant metformin and simvastatinMetformin and Simvastatin in Invasive Bladder Cancer

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on metformin + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + simvastatin.

Explore the full profile